Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance

Journal of Biotechnology

Volumn 202, Issue , 2015, Pages 40-49

  Khalil, Hilal S ^a   Mitev, Vanio ^b   Vlaykova, Tatyana ^c   Cavicchi, Laura ^a   Zhelev, Nikolai ^a  

^a UNIVERSITY OF ABERTAY DUNDEE   (United Kingdom)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^c TRAKIA UNIVERSITY   (Bulgaria)

Author keywords

CDK; Seliciclib; Systems biology

Indexed keywords

CELL PROLIFERATION;

ANTI-CANCER AGENTS; CLINICAL TESTING; DRUG DEVELOPMENT; KINASE INHIBITORS; MOLECULAR PATHWAYS; SELICICLIB; SYSTEMS BIOLOGY; THERAPEUTIC EFFECTS;

BIOLOGY;

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; ROSCOVITINE;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG REPOSITIONING; HUMAN; PROCEDURES; SYSTEMS BIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; CYCLIN-DEPENDENT KINASES; DRUG REPOSITIONING; HUMANS; PROTEIN KINASE INHIBITORS; PURINES; SYSTEMS BIOLOGY;

EID: 84939986753     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2015.02.032     Document Type: Article

References (129)

1. Abal M., Bras-Goncalves R., Judde J.-G., Fsihi H., De Cremoux P., Louvard D., Magdelenat H., Robine S., Poupon M.-F. Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene 2004, 23:1737-1744.
2. Agbottah E., de La Fuente C., Nekhai S., Barnett A., Gianella-Borradori A., Pumfery A., Kashanchi F. Antiviral activity of CYC202 in HIV-1-infected cells. J. Biol. Chem. 2005, 280:3029-3042.
3. Alessi F., Quarta S., Savio M., Riva F., Rossi L., Stivala L.A., Scovassi A.I., Meijer L., Prosperi E. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp. Cell Res. 1998, 245:8-18.
4. Angelo M., Plattner F., Giese K.P. Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory. J. Neurochem. 2006, 99:353-370.
5. Anon Dorland's Illustrated Medical Dictionary 2007, Saunders Elsevier, Philadelphia. 31st ed.
6. Anon PKD International Webpage 2014, International Webpage, (accessed 28.12.14). http://www.pkdinternational.org/what-is-pkd/.
7. Atanasova G., Jans R., Zhelev N., Mitev V., Poumay Y. Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes. Biochem. Pharmacol. 2005, 70:824-836.
8. Atanasova G.N., Isaeva A.R., Zhelev N., Poumay Y., Mitev V.I. Effects of the CDK-inhibitor CYC202 on p38 MAPK, ERK1/2 and c-Myc activities in papillomavirus type 16 E6- and E7-transformed human keratinocytes. Oncol. Rep. 2007, 18:999-1005.
9. Aydemir A., Abbasoglu O., Topaloglu S., Ertoy D., Ayhan A., Kilinç K., Karabulut E., Sayek I. Protective effect of roscovitine on renal ischemia-reperfusion injury. Transplant. Proc. 2002, 34:2027-2028.
10. De Azevedo W.F., Leclerc S., Meijer L., Havlicek L., Strnad M., Kim S.H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. FEBS 1997, 243:518-526.
11. Bain J., McLauchlan H., Elliott M., Cohen P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003, 371:199-204.
12. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S.C., Alessi D.R., Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408:297-315.
13. Benson C., White J., De Bono J., O'Donnell A., Raynaud F., Cruickshank C., McGrath H., Walton M., Workman P., Kaye S., Cassidy J., Gianella-Borradori A., Judson I., Twelves C. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br. J. Cancer 2007, 96:29-37.
14. Berthet C., Aleem E., Coppola V., Tessarollo L., Kaldis P. Cdk2 knockout mice are viable. Curr. Biol. 2003, 13:1775-1785.
15. Biglione S., Byers S.A., Price J.P., Nguyen V.T., Bensaude O., Price D.H., Maury W. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 2007, 4:47.
16. Boeing S., Rigault C., Heidemann M., Eick D., Meisterernst M. RNA polymerase II C-terminal heptarepeat domain Ser-7 phosphorylation is established in a mediator-dependent fashion. J. Biol. Chem. 2010, 285:188-196.
17. Bukanov N.O., Smith L.A., Klinger K.W., Ledbetter S.R., Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006, 444:949-952.
18. Chagniel L., Robitaille C., Lebel M., Cyr M. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model. Neurobiol. Dis. 2012, 45:645-655.
19. Cheng C.K., Gustafson W.C., Charron E., Houseman B.T., Zunder E., Goga A., Gray N.S., Pollok B., Oakes S.A., James C.D., Shokat K.M., Weiss W.A., Fan Q.-W. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:12722-12727.
20. Cheung Z.H., Ip N.Y. Cdk5: a multifaceted kinase in neurodegenerative diseases. Trends Cell Biol. 2012, 22:169-175.
21. Chiarle R., Pagano M., Inghirami G. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res. 2001, 3:91-94.
22. Clark E., Santiago F., Deng L., Chong S., de La Fuente C., Wang L., Fu P., Stein D., Denny T., Lanka V., Mozafari F., Okamoto T., Kashanchi F. Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1. J. Virol. 2000, 74:5040-5052.
23. Clavien P.A., Harvey P.R., Strasberg S.M. Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. Transplantation 1992, 53:957-978.
24. Clyde R., Tummala H., Khalil H.S., Goszcz K., Lucka I., Tupone M.G., Zwirek M., Cavicchi L., Vallatur J., Stoyanova V., Mitev V., Zhelev N. A novel quantitative systems biology approach to cancer research and treatment. Curr. Opin. Biotechnol. 2011, 22:S58.
25. Clyde R.G., Bown J.L., Hupp T.R., Zhelev N., Crawford J.W. The role of modelling in identifying drug targets for diseases of the cell cycle. J. R. Soc. Interface 2006, 3:617-627.
26. Cruz J.C., Tsai L.-H. A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr. Opin. Neurobiol. 2004, 14:390-394.
27. Cyclacel Cyclacel Press Release 09/04/13 2013, Cyclacel Website, (accessed 11.07.14). http://investor.cyclacel.com/releasedetail.cfm?.ReleaseID=755324.
28. Cyclacel Cyclacel Press Release 12/08/13 2013, Cyclacel Website, (accessed 11.07.14). http://investor.cyclacel.com/releasedetail.cfm?.ReleaseID=785366.
29. Cyclacel Cyclacel Press Release 21/12/10 2010, Cyclacel Website, (accessed 11.07.14). http://investor.cyclacel.com/releasedetail.cfm?.ReleaseID=614395.
30. Cyclacel Cyclacel Press Release 29/05/08 2008, Cyclacel Website, (accessed 11.07.14). http://investor.cyclacel.com/releasedetail.cfm?.ReleaseID=624917.
31. Dhavan R., Tsai L.H. A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2001, 2:749-759.
32. Durand L.O., Roizman B. Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1. J. Virol. 2008, 82:10591-10599.
33. FDA NDA Approvals Receipts 18/01/2013 2013, FDA Website.
34. Fleming I.N., Hogben M., Frame S., McClue S.J., Green S.R. Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. Clin. Cancer Res. 2008, 14:4326-4335.
35. Goltsov A., Deeni Y., Khalil H.S., Soininen T., Kyriakidis S., Hu H., Langdon S.P., Harrison D.J., Bown J. Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy. Cells 2014, 3:563-591.
36. Goltsov A., Langdon S.P., Goltsov G., Harrison D.J., Bown J. Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations. Front. Oncol. 2014, 4:13.
37. Goodyear S., Sharma M.C. Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5. Exp. Mol. Pathol. 2007, 82:25-32.
38. Graña X., Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995, 11:211-219.
39. Havlícek L., Hanus J., Veselý J., Leclerc S., Meijer L., Shaw G., Strnad M. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem. 1997, 40:408-412.
40. Hoogendijk A.J., Roelofs J.J.T.H., Duitman J., van Lieshout M.H.P., Blok D.C., van der Poll T., Wieland C.W. R-roscovitine reduces lung inflammation induced by lipoteichoic acid and Streptococcus pneumoniae. Mol. Med. (Cambridge, MA) 2012, 18:1086-1095.
41. Hsieh W.-S., Soo R., Peh B.-K., Loh T., Dong D., Soh D., Wong L.-S., Green S., Chiao J., Cui C.-Y., Lai Y.-F., Lee S.-C., Mow B., Soong R., Salto-Tellez M., Goh B.-C. Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin. Cancer Res. 2009, 15:1435-1442.
42. Huber R.J., O'Day D.H. The cyclin-dependent kinase inhibitor roscovitine inhibits kinase activity, cell proliferation, multicellular development, and Cdk5 nuclear translocation in Dictyostelium discoideum. J. Cell. Biochem. 2012, 113:868-876.
43. Hui A.B.Y., Yue S., Shi W., Alajez N.M., Ito E., Green S.R., Frame S., O'Sullivan B., Liu F.-F. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Clin. Cancer Res. 2009, 15:3716-3724.
44. Hung K.-S., Hwang S.-L., Liang C.-L., Chen Y.-J., Lee T.-H., Liu J.-K., Howng S.-L., Wang C.-H. Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats. J. Neuropathol. Exp. Neurol. 2005, 64:15-26.
45. Idowu M., Khalil H.S., Brown J.L., Zhelev N. Reverse engineering of drug induced DNA damage response signalling pathway reveals dual outcomes of ATM kinase inhibition. BioDiscovery 2013, 9:4.
46. Idowu M.A., Goltsov A., Khalil H.S., Tummala H., Zhelev N., Bown J. Cancer research and personalised medicine: a new approach to modelling time-series data using analytical methods and Half systems. Curr. Opin. Biotechnol. 2011, 22:S59.
47. Iseki H., Ko T.C., Xue X.Y., Seapan A., Hellmich M.R., Townsend C.M. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells. Surgery 1997, 122:187-194. discussion 194-195.
48. Iseki H., Ko T.C., Xue X.Y., Seapan A., Townsend C.M. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity. J. Gastrointest. Surg. 1998, 2:36-43.
49. Ivanov A., Tyzio R., Zilberter Y., Ben-Ari Y. (R)-roscovitine, a cyclin-dependent kinase inhibitor, enhances tonic GABA inhibition in rat hippocampus. Neuroscience 2008, 156:277-288.
50. Kasai H., Imamura T., Tsuruma K., Takahashi Y., Kurasawa T., Hirata H., Shimazawa M., Hara H. Effects of roscovitine, a cell cyclin [correction of cycling]-dependent kinase inhibitor, on intraocular pressure of rabbit and retinal ganglion cell damage. Neurosci. Lett. 2013, 535:95-99.
51. Khalil H., Tummala H., Chakarov S., Zhelev N., Lane D. Targeting ATM pathway for therapeutic intervention in cancer. Biodiscovery 2012, 1:3.
52. Krystof V., Chamrád I., Jorda R., Kohoutek J. Pharmacological targeting of CDK9 in cardiac hypertrophy. Med. Res. Rev. 2010, 30:646-666.
53. Kusakawa G., Saito T., Onuki R., Ishiguro K., Kishimoto T., Hisanaga S. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J. Biol. Chem. 2000, 275:17166-17172.
54. Labbé J.C., Capony J.P., Caput D., Cavadore J.C., Derancourt J., Kaghad M., Lelias J.M., Picard A., Dorée M. MPF from starfish oocytes at first meiotic metaphase is a heterodimer containing one molecule of cdc2 and one molecule of cyclin B. EMBO J. 1989, 8:3053-3058.
55. Lacrima K., Valentini A., Lambertini C., Taborelli M., Rinaldi A., Zucca E., Catapano C., Cavalli F., Gianella-Borradori A., Maccallum D.E., Bertoni F. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann. Oncol. 2005, 16:1169-1176.
56. Lambert L.A., Qiao N., Hunt K.K., Lambert D.H., Mills G.B., Meijer L., Keyomarsi K. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res. 2008, 68:7966-7974.
57. Langdale L.A., Flaherty L.C., Liggitt H.D., Harlan J.M., Rice C.L., Winn R.K. Neutrophils contribute to hepatic ischemia-reperfusion injury by a CD18-independent mechanism. J. Leukoc. Biol. 1993, 53:511-517.
58. Larochelle S., Pandur J., Fisher R.P., Salz H.K., Suter B. Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity. Genes Dev. 1998, 12:370-381.
59. Lebedeva G., Sorokin A., Faratian D., Mullen P., Goltsov A., Langdon S.P., Harrison D.J., Goryanin I. Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network. Eur. J. Pharm. Sci. 2012, 46:244-258.
60. Lee H.R., Chang T.H., Tebalt M.J., Senderowicz A.M., Szabo E. Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line. Int. J. Oncol. 1999, 15:161-166.
61. Leitch A.E., Haslett C., Rossi A.G. Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents. Br. J. Pharmacol. 2009, 158:1004-1016.
62. Leitch A.E., Lucas C.D., Marwick J.A., Duffin R., Haslett C., Rossi A.G. Cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation. Cell Death Differ. 2012, 19:1950-1961.
63. Lolli G., Johnson L.N. CAK-cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs?. Cell cycle (Georgetown, Tex.) 2005, 4:572-577.
64. Lopes J.P., Oliveira C.R., Agostinho P. Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies. Cell. Mol. Neurobiol. 2007, 27:943-957.
65. Loyer P., Trembley J.H., Katona R., Kidd V.J., Lahti J.M. Role of CDK/cyclin complexes in transcription and RNA splicing. Cell. Signal. 2005, 17:1033-1051.
66. Lu W., Chen L., Peng Y., Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001, 20:3206-3216.
67. Maldonado E., Reinberg D. News on initiation and elongation of transcription by RNA polymerase II. Curr. Opin. Cell Biol. 1995, 7:352-361.
68. Malumbres M., Barbacid M. Cell cycle kinases in cancer. Curr. Opin. Genet. Dev. 2007, 17:60-65.
69. Malumbres M., Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 2005, 30:630-641.
70. Martinez J.R., Grantham J.J. Polycystic kidney disease: etiology, pathogenesis, and treatment. Dis. Mon. 1995, 41:693-765.
71. McClue S.J., Blake D., Clarke R., Cowan A., Cummings L., Fischer P.M., MacKenzie M., Melville J., Stewart K., Wang S., Zhelev N., Zheleva D., Lane D.P. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 2002, 102:463-468.
72. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., Moulinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. FEBS 1997, 243:527-536.
73. Meijer L., Galons H. CDK inhibitors and their potential as anti-tumor agents. Monographs on Enzyme Inhibitors, Vol. 2 2006, 187-226. CRC Press/Taylor & Francis. P. Smith, E. Yue (Eds.).
74. Meijer L., Guerrier P. Maturation and fertilization in starfish oocytes. Int. Rev. Cytol. 1984, 86:129-196.
75. Menn B., Bach S., Blevins T.L., Campbell M., Meijer L., Timsit S. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS ONE 2010, 5:e12117.
76. Mgbonyebi O.P., Russo J., Russo I.H. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res. 1999, 59:1903-1910.
77. Mgbonyebi O.P., Russo J., Russo I.H. Roscovitine inhibits the proliferative activity of immortal and neoplastic human breast epithelial cells. Anticancer Res. 1998, 18:751-755.
78. Milovanceva-Popovska M., Kunter U., Ostendorf T., Petermann A., Rong S., Eitner F., Kerjaschki D., Barnett A., Floege J. R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury. Kidney Int. 2005, 67:1362-1370.
79. Mohapatra S., Chu B., Zhao X., Pledger W.J. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res. 2005, 65:7717-7723.
80. Morgan D.O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 1997, 13:261-291.
81. Nair B.C., Vallabhaneni S., Tekmal R.R., Vadlamudi R.K. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Res. 2011, 13:R80.
82. Neant I., Guerrier P. 6-Dimethylaminopurine blocks starfish oocyte maturation by inhibiting a relevant protein kinase activity. Exp. Cell Res. 1988, 176:68-79.
83. Nechaev S., Adelman K. Pol II waiting in the starting gates: regulating the transition from transcription initiation into productive elongation. Biochim. Biophys. Acta 2011, 1809:34-45.
84. Pérez de Castro I., de Cárcer G., Malumbres M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 2007, 28:899-912.
85. Pippin J.W., Qu Q., Meijer L., Shankland S.J. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. J. Clin. Investig. 1997, 100:2512-2520.
86. Pondaven P., Meijer L., Beach D. Activation of M-phase-specific histone H1 kinase by modification of the phosphorylation of its p34cdc2 and cyclin components. Genes Dev. 1990, 4:9-17.
87. Prithviraj R., Trunova S., Giniger E. Ex vivo culturing of whole, developing Drosophila brains. J. Vis. Exp. 2012.
88. Raynaud F.I., Whittaker S.R., Fischer P.M., McClue S., Walton M.I., Barrie S.E., Garrett M.D., Rogers P., Clarke S.J., Kelland L.R., Valenti M., Brunton L., Eccles S., Lane D.P., Workman P. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin. Cancer Res. 2005, 11:4875-4887.
89. Rebhun L.I., White D., Sander G., Ivy N. Cleavage inhibition in marine eggs by puromycin and 6-dimethylaminopurine. Exp. Cell Res. 1973, 77:312-318.
90. Rechter S., Scott G.M., Eickhoff J., Zielke K., Auerochs S., Müller R., Stamminger T., Rawlinson W.D., Marschall M. Cyclin-dependent kinases phosphorylate the cytomegalovirus RNA export protein pUL69 and modulate its nuclear localization and activity. J. Biol. Chem. 2009, 284:8605-8613.
91. Rialet V., Meijer L. A new screening test for antimitotic compounds using the universal M phase-specific protein kinase, p34cdc2/cyclin Bcdc13, affinity-immobilized on p13suc1-coated microtitration plates. Anticancer Res. 1991, 11:1581-1590.
92. Romano G., Giordano A. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle (Georgetown, TX.) 2008, 7:3664-3668.
93. Rossi A.G., Sawatzky D.A., Walker A., Ward C., Sheldrake T.A., Riley N.A., Caldicott A., Martinez-Losa M., Walker T.R., Duffin R., Gray M., Crescenzi E., Martin M.C., Brady H.J., Savill J.S., Dransfield I., Haslett C. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med. 2006, 12:1056-1064.
94. Sadleir K.R., Vassar R. Cdk5 protein inhibition and Aβ42 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease. J. Biol. Chem. 2012, 287:7224-7235.
95. Sanchez V., McElroy A.K., Spector D.H. Mechanisms governing maintenance of Cdk1/cyclin B1 kinase activity in cells infected with human cytomegalovirus. J. Virol. 2003, 77:13214-13224.
96. Schafer K.A. The cell cycle: a review. Vet. Pathol. 1998, 35:461-478.
97. Schang L.M., Phillips J., Schaffer P.A. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J. Virol. 1998, 72:5626-5637.
98. Schang L.M., Rosenberg A., Schaffer P.A. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. J. Virol. 1999, 73:2161-2172.
99. Schang L.M., St Vincent M.R., Lacasse J.J. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir. Chem. Chemother. 2006, 17:293-320.
100. Schutte B., Nieland L., van Engeland M., Henfling M.E., Meijer L., Ramaekers F.C. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp. Cell Res. 1997, 236:4-15.
101. Sheryanna A.M., Smith J., Bhangal G., Barnett A., McClue S., Tam F.W.K., Cook T., Pusey C.D. Treatment with a cyclin-dependent kinase inhibitor, seliciclib, is effective in reducing glomerular macrophage numbers and the severity of established experimental glomerulonephritis. Nephrology (Carlton, VIC) 2011, 16:410-416.
102. Shoemaker R.H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 2006, 6:813-823.
103. Siegel-Lakhai W., Rodenstein D., Beijnen J., Gianella-Borradori A., Schellens J., Talbot D. Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2005, 23:150.
104. Steinman R.A., Robinson A.R., Feghali-Bostwick C.A. Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts. PLoS ONE 2012, 7:e48560.
105. Strock C.J., Park J.-I., Nakakura E.K., Bova G.S., Isaacs J.T., Ball D.W., Nelkin B.D. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res. 2006, 66:7509-7515.
106. Tirado O.M., Mateo-Lozano S., Notario V. Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Cancer Res. 2005, 65:9320-9327.
107. Topaloglu S., Abbasoglu O., Ayhan A., Sokmensuer C., Kilinc K. Antiapoptotic and protective effects of roscovitine on ischemia-reperfusion injury of the rat liver. Liver Int. 2003, 23:300-307.
108. Le Tourneau C., Faivre S., Laurence V., Delbaldo C., Vera K., Girre V., Chiao J., Armour S., Frame S., Green S.R., Gianella-Borradori A., Diéras V., Raymond E. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur. J. Cancer (Oxford, England: 1990) 2010, 46:3243-3250.
109. Trifonov D., Tummala H., Clements S., Zhelev N. Effect of roscovitine on cardiac hypertrophy in human stem cell derived cardiomyocytes. Curr. Opin. Biotechnol. 2013, 24:S114-S115.
110. Tummala H., Goltsov A., Khalil H., Sproul A., Scott F., Mitev V., Zhelev N. Advocating the need of a systems biology approach for personalised prognosis and treatment of B-CLL patients. Biodiscovery 2012, 6:4.
111. Veselý J., Havlicek L., Strnad M., Blow J.J., Donella-Deana A., Pinna L., Letham D.S., Kato J., Detivaud L., Leclerc S. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. FEBS 1994, 224:771-786.
112. Wallenfang M.R., Seydoux G. cdk-7 Is required for mRNA transcription and cell cycle progression in Caenorhabditis elegans embryos. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:5527-5532.
113. Wang S., Fischer P.M. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol. Sci. 2008, 29:302-313.
114. Wen H., Linhoff M.W., Hubbard J.M., Nelson N.R., Stensland D., Dallman J., Mandel G., Brehm P. Zebrafish calls for reinterpretation for the roles of P/Q calcium channels in neuromuscular transmission. J. Neurosci. 2013, 33:7384-7392.
115. Wesierska-Gadek J., Gueorguieva M., Horky M. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol. Cancer Ther. 2005, 4:113-124.
116. Wesierska-Gadek J., Wandl S., Kramer M.P., Pickem C., Krystof V., Hajek S.B. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells. J. Cell. Biochem. 2008, 105:1161-1171.
117. Whittaker S., Walton M., Kelland L., Garrett M., Zhelev N., Workman P. Rb Phorphorylation as a pharmacodynamic marker of Roscovitine (CYC202) activity in vitro and in vivo. Proc. Am. Assoc. Cancer Res. 2001, 42:926.
118. Wu L., Chen P., Hwang J.J., Barsky L.W., Weinberg K.I., Jong A., Starnes V.A. RNA antisense abrogation of MAT1 induces G1 phase arrest and triggers apoptosis in aortic smooth muscle cells. J. Biol. Chem. 1999, 274:5564-5572.
119. Yakisich J.S., Boethius J., Lindblom I.O., Wallstedt L., Vargas V.I., Sidén A., Cruz M.H. Inhibition of DNA synthesis in human gliomas by roscovitine. Neuroreport 1999, 10:2563-2567.
120. Yang X., Gold M.O., Tang D.N., Lewis D.E., Aguilar-Cordova E., Rice A.P., Herrmann C.H. TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:12331-12336.
121. Yeo W., Goh B., Le Tourneau C., Green S., Siu J., Chiao L. A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma. J. Clin. Oncol. 2009, 27:6026.
122. Yu D.S., Cortez D. A role for CDK9-cyclin K in maintaining genome integrity. Cell Cycle (Georgetown, Tex.) 2011, 10:28-32.
123. Zhang G.-J., Safran M., Wei W., Sorensen E., Lassota P., Zhelev N., Neuberg D.S., Shapiro G., Kaelin W.G. Bioluminescent imaging of Cdk2 inhibition in vivo. Nat. Med. 2004, 10:643-648.
124. Zhang M., Li J., Chakrabarty P., Bu B., Vincent I. Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am. J. Pathol. 2004, 165:843-853.
125. Zhelev N., Khalil H.S., Adebola Oluwaseun O., Uth K., D'Ascanio I., Stoyanova V., Vlaykova T., Mitev V. Systems biology approach in the discovery and development of cyclin-dependent kinase inhibitors as new therapeutics in oncology and cardiology. J. Biotechnol. Biomater. 2014, 3:82.
126. Zhelev N., Trofonov D., Wang S., Hassan M., El Serafi I., Mitev V. From Roscovitine to CYC202 to Seliciclib - from bench to bedside: discovery and development. Biodiscovery 2013, 10:1.
127. Zhelev N., Tummala H., Trifonov D., D'Ascanio I., Adebola Oluwaseun O., Fischer P.M. Recent advances in the development of cyclin-dependent kinase inhibitors as new therapeutics in oncology and cardiology. Curr. Opin. Biotechnol. 2013, 24:S25.
128. Zhivotovsky B., Orrenius S. Cell cycle and cell death in disease: past, present and future. J. Intern. Med. 2010, 268:395-409.
129. Zoja C., Casiraghi F., Conti S., Corna D., Rottoli D., Cavinato R.A., Remuzzi G., Benigni A. Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. Arthritis Rheum. 2007, 56:1629-1637.